Medtronic plc - MDT STOCK NEWS

Medtronic plc (NYSE:MDT) has initiated the ALLEVIATE-HF clinical trial to assess the effectiveness of its Reveal LINQ™ Insertable Cardiac Monitor (ICM) in detecting patients at high risk of worsening heart failure. The study will enroll up to 300 patients across 30 sites in the U.S. over a minimum follow-up period of seven months to three years. The LINQ device wirelessly monitors heart conditions and alerts clinicians of potential heart failure risks, enabling timely interventions. Heart failure affects 6.2 million Americans, emphasizing the importance of this technology in proactive patient management.

Medtronic plc (NYSE:MDT) has achieved FDA Breakthrough Device Designation for its TYRX™ Absorbable Antibacterial Driveline Wrap. This device supports patients with ventricular assist devices (VAD) by minimizing the risk of infection associated with the percutaneous driveline. The wrap releases antimicrobial agents over a minimum of seven days and is designed to be fully absorbed approximately nine weeks post-implantation. The Breakthrough Device Program ensures expedited review and communication from the FDA to facilitate timely access to critical medical technologies.

Medtronic plc (NYSE: MDT) released data from the WRAP-IT study, indicating that the TYRX Absorbable Antibacterial Envelope is cost-effective for patients with elevated infection risks receiving cardiac implantable electronic devices (CIEDs). The ICER of the envelope remains below the recommended threshold of $150,000, demonstrating significant cost-efficiency compared to standard infection prevention methods. Long-term data reveals a 40% reduction in major CIED infections and sustained benefits over three years. This innovation received endorsement from major medical societies and recognition as a top medical innovation for 2020.

Medtronic plc (NYSE: MDT) announced its participation in the Morgan Stanley 18th Annual Global Healthcare Conference, scheduled for September 14, 2020. CEO Geoff Martha will address questions starting at 1:30 p.m. EDT. A live audio webcast will be accessible via Medtronic's investor relations page, with an archived version available post-event. Medtronic, headquartered in Dublin, Ireland, is a leading medical technology company focused on improving healthcare worldwide, employing over 90,000 people in 150+ countries.

Medtronic plc (NYSE: MDT) reported key findings from the PRODIGY study, revealing that opioid-induced respiratory depression (OIRD) occurred in 46% of patients monitored. The study also established the PRODIGY Risk Score, a tool to identify high-risk patients for OIRD, which can lead to longer hospital stays and increased adverse events. This research assessed 1,335 patients across multiple regions, indicating a significant predictive capability for respiratory risks, thus enhancing patient safety during opioid administration.

Medtronic plc (NYSE:MDT) has received FDA approval for an early feasibility study of its Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) system, targeting severe tricuspid regurgitation—a condition affecting over 2 million patients in the U.S. The study follows the recent Breakthrough Device Designation for the TTVR system, aimed at improving treatment access for high-risk patients. Experts express optimism that the trial will enhance understanding of this serious condition and lead to further innovations in therapy.

Medtronic plc (NYSE:MDT) will participate in the Wells Fargo Securities 2020 Virtual Healthcare Conference on September 10, 2020. The event features Karen Parkhill, executive vice president and CFO, answering questions starting at 10:40 a.m. EDT. A live webcast will be accessible through the Investor Events link on the company’s website. An archive will be available later that day. Medtronic, headquartered in Dublin, is a leader in medical technology, employing over 90,000 people globally. It focuses on improving health outcomes worldwide.

Medtronic plc (NYSE:MDT) has received FDA approval for its MiniMed™ 770G hybrid closed-loop insulin pump system, enhancing diabetes management for children as young as 2. This advanced system includes SmartGuard™ technology with smartphone connectivity, allowing caregivers to monitor real-time glucose levels and share data with clinicians. The MiniMed 770G aims to improve clinical outcomes based on evidence from a clinical study, indicating no severe hypoglycemia or device-related adverse events. Orders for the system will begin in the United States this week.

DUBLIN, Aug. 29, 2020 – Medtronic (NYSE: MDT) announced positive clinical trial results for its Arctic Front™ Advance Cryoballoon and Freezor® MAX Catheter. In the STOP-AF First trial, cryoablation proved superior to antiarrhythmic drugs (AAD) for treating recurrent symptomatic paroxysmal atrial fibrillation (PAF), with a 75% success rate compared to 45% for AAD. The Cryo-FIRST trial further showed significant quality of life improvements with the cryoablation system. The Arctic Front Advance is FDA-approved for treating symptomatic recurrent persistent AF, expanding treatment options for patients.